Please login to the form below

Not currently logged in
Email:
Password:

Merck says osteoporosis drug clears phase II trial

Odanacatib on track for 2013 filing

A phase II trial of Merck & Co's osteoporosis drug candidate has yielded positive results, putting the programme on track for regulatory filings in 2013, says the company.

Odanacatib - currently leading a new class of osteoporosis drugs called cathepsin K inhibitors - has already shown efficacy in reducing fractures in a phase III trial and has been tipped to make sales of $3bn or more at peak.

The latest phase II data indicate that odanacatib significantly increased bone mineral density (BMD) over a two-year period in post-menopausal women with osteoporosis who previously had three or more years of treatment with alendronate, a long-standing drug for the disease which Merck sells as Fosamax.

Patients in the study were randomised to receive either odanacatib or placebo once a week on top of calcium and vitamin D supplements if needed.

At the end of the two-year treatment period, Merck's drug raised BMD by around 1 to 2 per cent - depending on the site tested - while the placebo group saw declines of around the same margin. For example, lumbar spine density increased over 2 per cent with odanacatib but decline by 0.3 per cent in the placebo group.

"We're excited about these results because understanding the effects of odanacatib in a population of post-menopausal women previously treated for osteoporosis is important to clinicians," said Albert Leung, executive director of clinical research at Merck Research Laboratories.

Critically, odanacatib has a favourable safety profile compared to older bisphosphonate-based medicines for osteoporosis like Fosamax, which are associated with gastrointestinal problems as well as rare cases in which bone tissue can start to decay.

Odanacatib is one of five drugs in development at Merck that it hopes will help it return to buoyant growth since losing patent protection on some of its blockbuster brands, notably $6bn-a-year asthma and allergy treatment Singulair (montelukast).

Others include first-in-class insomnia treatment suvorexant, neuromuscular reversal agent Bridion (sugammadex), HPV vaccine V503, and atherosclerosis medicine Tredaptive ER (nicotinic acid/laropiprant).

15th October 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashley Communications

Ashley Communications is a unique medical communications consultancy providing outstandingdirector-only service tailored to individual client needs. The company philosophy is...

Latest intelligence

The vitamin D deficiency: should we act?
Healthcare PR agency Say Communications analyses whether headlines are able to trigger a behavioural change with regards to the vitamin D deficiency issue....
Is obesity the new smoking?
Is obesity the new smoking? The healthcare PR team at Say communications analyses the question posed by NHS Chief executive Simon Stevens....
Children, the weight issue and how we deal with this responsibly?
Say Communication, Healthcare PR Agency, looks at how children deal with the weight issue and how we can approach it responsibly....

Infographics